Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systems neuropharmacology of nicotine in aversive learning in humans
DRKS00025233Phase 4Completed
- Sponsor
- Institut für Systemische Neurowissenschaften
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nicotine (3 arms), sponsored by Institut für Systemische Neurowissenschaften. Primary endpoints: Discrimination between CS+ and CS- during acquisition on day 1 and Discrimination between CS+ and CS- during extinction and reinstatement on day 2. Started Feb 2022; status: completed.
02
Drugs
nicotine
Beyond the preview
Go deeper on DRKS00025233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00025233.